Table 4.
Adverse outcomes of breast reconstructions in Hodgkin lymphoma survivors compared with matched controls: stratified per reconstruction type.
| Breast reconstructions in HL survivors | Controls | P | |
|---|---|---|---|
| Direct-to-implant | |||
| n | 29 | 55 | |
| Failure or conversion of breast reconstruction due to a complication, n (%) | 5 (17.2) | 8 (14.5) | 0.759 |
| Reoperations due to a complication, n (%) | |||
| 0 | 20 (69.0) | 36 (65.5) | 1.000 |
| 1 | 6 (20.7) | 12 (21.8) | |
| 2+ | 3 (10.3) | 7 (12.7) | |
| Capsular contracture, n (%) | 1 (3.4) | 8 (14.5) | 0.154 |
| Tissue expander/implant | |||
| n | 19 | 34 | |
| Failure or conversion of breast reconstruction due to a complication, n (%) | 3 (15.8) | 5 (14.7) | 1.000 |
| Reoperations due to a complication, n (%) | |||
| 0 | 12 (63.2) | 18 (52.9) | 0.001a |
| 1 | 2 (10.5) | 16 (47.1) | |
| 2+ | 5 (26.3) | 0 (0.0) | |
| Capsular contracture, n (%) | 2 (10.5) | 9 (26.5) | 0.290 |
| Autologous with implant | |||
| n | 8 | 10 | |
| Failure or conversion of breast reconstruction due to a complication, n (%) | 0 (0.0) | 2 (20.0) | 0.477 |
| Reoperations due to a complication, n (%) | |||
| 0 | 7 (87.5) | 6 (60.0) | 0.588 |
| 1 | 1 (12.5) | 2 (20.0) | |
| 2+ | 0 (0.0) | 2 (20.0) | |
| Capsular contracture, n (%) | 0 (0.0) | 0 (0.0) | 1.000 |
| Major donor-site complications, n (%) | 0 (0.0) | 0 (0.0) | 1.000 |
| Autologous only | |||
| n | 14 | 22 | |
| Failure or conversion of breast reconstruction due to a complication, n (%) | 1 (7.1) | 0 (0.0) | 0.389 |
| Reoperations due to a complication, n (%) | |||
| 0 | 7 (50.0) | 17 (77.3) | 0.200 |
| 1 | 5 (35.7) | 3 (13.6) | |
| 2+ | 2 (14.3) | 2 (9.1) | |
| Major donor-site complications, n (%) | 2 (14.3) | 4 (18.2) | 1.000 |
HL, Hodgkin lymphoma.
a
Indicates a significant test result.